Bridgeway Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
Other funds holding ZNTL
Bridgeway Capital Management's ZNTL Position: Q3 2026 in Review
Bridgeway Capital Management reduced its Zentalis Pharmaceuticals (ZNTL) stake by 1.7% in Q3 2026, selling an estimated $5.26K and leaving 75,996 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #1011.
Bridgeway Capital Management first reported a position in ZNTL in Q4 2024 and has held it in 8 quarters since. The position peaked at $530K in Q4 2024. 128 funds tracked by Wall St. Rank hold ZNTL as of Q3 2026.
- Bridgeway Capital Management held 75,996 shares of Zentalis Pharmaceuticals worth $211K as of Q3 2026.
- Bridgeway Capital Management sold 1,304 Zentalis Pharmaceuticals shares in Q3 2026, an estimated $5.26K.
- Zentalis Pharmaceuticals made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #1011 holding.
- Bridgeway Capital Management first reported a position in Zentalis Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
- Bridgeway Capital Management's Zentalis Pharmaceuticals position peaked at $530K in Q4 2024.
- 128 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.